Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for sarcoidosis patients: inhaled drug targets lung and heart strain

NCT ID NCT03814317

First seen Feb 06, 2026 · Last updated May 21, 2026 · Updated 17 times

Summary

This study tested an inhaled medication called treprostinil in 5 people with sarcoidosis who also have lung scarring and high blood pressure in the lungs. The goal was to see if the drug could improve blood flow and heart function. Participants took the drug and were monitored with heart tests, walking tests, and breathing tests over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Florida, Division of Pulmonary and Critical Care Medicine

    Gainesville, Florida, 32610, United States

Conditions

Explore the condition pages connected to this study.